Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures

References

• Holland J F, Frei E, III, Bast R, Jr, Kufe D, Morton D, Weichselbaum R. Cancer Medicine. Anticancer Drugs from Plants: Vinca Alkaloids and Taxanes4th ed., W T Beck, C E Cass, P J Houghton. Williams & Wilkins, Baltimore 1997; 1: 1011
   Google Scholar
• DeMott T K, Richardson J K, Thies S B, Ashton-Miler J A. Falls and gait characteristics among older persons with peripheral neuropathy. Am J Phys Med Rehabil 2007; 86: 125–132
   PubMed Web of Science ®Google Scholar
• Koski K, Luukinen H, Laippala P, Kivelä S. Risk factors for major injurious falls among the home-dwelling elderly by functional abilities. Gerontology 1998; 44: 232–238
   PubMed Web of Science ®Google Scholar
• Richardson J K, Hurvitz E A. Peripheral neuropathy: a true risk factor for falls. J Gerontol A Biol Sci Med Sci 1995; 50: M211–M215
   PubMed Web of Science ®Google Scholar
• Ansell S M, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1087–1097
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation: Disease facts, http://www.nof.org/osteoporosis/diseasefacts.html
   Google Scholar
• Reginster J Y, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006; 38(2 Suppl 1)S4–S9
   PubMed Web of Science ®Google Scholar
• International Osteopososis Foundation: Epidemiology, http://www.iofbonehealth.org/health-professionals/about-osteoporosis/epidemiology.html
   Google Scholar
• Shapiro C L, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306–3311
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon R A, Cuzick J, Dowsett M, Clack G, Adams J E. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215–1223
   PubMed Web of Science ®Google Scholar
• Stoch S A, Parker R A, Chen L, Bubley G, Ko Y J, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787–2791
   PubMed Web of Science ®Google Scholar
• Lopez A M, Pena M A, Hernandez R, Val F, Martin B, Riancho J A. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005; 16: 707–711
   PubMed Web of Science ®Google Scholar
• Brown J E, Ellis S P, Silcocks P, Blumsohn A, Gutcher S A, Radstone C, et al. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res 2006; 12: 6480–6486
   PubMed Web of Science ®Google Scholar
• Holmes S J, Whitehouse R W, Clark S T, Crowther D C, Adams J E, Shalet S M. Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer 1994; 70: 371–375
   PubMed Web of Science ®Google Scholar
• Redman J R, Bajorunas D R, Wong G, McDermott K, Gnecco C, Schneider R, et al. Bone mineralization in women following successful treatment of Hodgkin's disease. Am J Med 1988; 85: 65–72
   PubMed Web of Science ®Google Scholar
• Potosky A L, Riley G F, Lubitz J D, Mentnech R M, Kessler L G. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732–748
   PubMed Web of Science ®Google Scholar
• Warren J L, Klabunde C N, Schrag D, Bach P B, Riley G F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40(Suppl IV)3–18
   Google Scholar
• Warren J L, Harlan L C, Fahey A, Virnig B A, Freeman J L, Klabunde C N, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002; 40(Suppl IV)55–61
   Google Scholar
• Ries L AG, Harkins D, Krapcho M, Marriotto A, Miller B A, Feuer E J, et al. SEER Cancer Statistics Review, 1975 – 2003. National Cancer Institute, Bethesda, MD 2006
   Google Scholar
• Zippin C, Lum D, Hankey B F. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76: 2343–2350
   PubMed Web of Science ®Google Scholar
• Du X, Goodwin J S. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001; 19: 1455–1461
   PubMed Web of Science ®Google Scholar
• Du X L, Key C R, Dickie L, Darling R, Geraci J M, Zhang D. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care 2006; 44: 124–131
   PubMed Web of Science ®Google Scholar
• US Public Health Services. International Classification of Diseases, 9th revision, Clinical Modification5th edn. Practice Management Information Corporation, Los Angeles 1996
   Google Scholar
• American Medical Association. Physicians' current procedural terminology-CPT 94. American Medical Association, Chicago 1993
   Google Scholar
• Health Care Financing Administration. HCFA common procedure coding system (HCPCS): national level II Medicare codes. Practice Management Information Corporation, Los Angeles 1994
   Google Scholar
• Health Care Financing Administration. HCFA Data Dictionary: Revenue Center Codes. Health Care Financing Administration, Baltimore, MD 1999
   Google Scholar
• Du X, Freeman J L, Goodwin J S. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance epidemiology and end results. J Clin Epidemiol 1999; 52: 463–470
   PubMed Web of Science ®Google Scholar
• Virnig B A, Warren J L, Cooper G S, Klabunde C N, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002; 40(Suppl IV)49–54
   Google Scholar
• Du X L, Chan W, Giordano S, Geraci J M, Delclos G L, Burau K, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer 2005; 104: 913–924
   PubMed Web of Science ®Google Scholar
• Klabunde C N, Potosky A L, Legler J M, Warren J L. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258–1267
   PubMed Web of Science ®Google Scholar
• Stokes M, Davis C, Koch G. Categoricia data analysis using the SAS system. SAS Institute, Cary, NC 1997
   Google Scholar
• Vermeulen A. Andropause. Maturitas 2000; 34: 5–15
   PubMed Web of Science ®Google Scholar
• Marystone J F, Barrett-Connor E L, Morton D J. Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Am J Public Health 1995; 85: 1693–1695
   PubMed Web of Science ®Google Scholar
• van Staa T P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79: 129–137
   PubMed Web of Science ®Google Scholar
• Kamischke A, Kemper D E, Castel M A, Luthke M, Rolf C, Behre H M, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11: 41–45
   PubMed Web of Science ®Google Scholar
• MacAdams M R, White R H, Chipps B E. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648–651
   PubMed Web of Science ®Google Scholar
• Szulc P, Claustrat B, Marchand F, Delmas P D. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003; 88: 5240–5247
   PubMed Web of Science ®Google Scholar
• Walsh M C, Kim N, Kadono Y, Rho J, Lee S Y, Lorenzo J, Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24: 33–63
   PubMed Web of Science ®Google Scholar
• Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S–17S, discussion 17S – 19S
   PubMed Web of Science ®Google Scholar
• Silverman S L. Quality-of-life issues in osteoporosis. Curr Rheumatol Rep 2005; 7: 39–45
   PubMedGoogle Scholar
• Cummings S R, Melton L J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761–1767
   PubMed Web of Science ®Google Scholar
• Deramond H, Saliou G, Aveillan M, Lehmann P, Vallee J N. Respective contributions of vertebroplasty and kyphoplasty to the management of osteoporotic vertebral fractures. Joint Bone Spine 2006; 73: 610–613
   PubMed Web of Science ®Google Scholar
• Gehlbach S BC, Heimisdottir M, May S, Walker M, Kirkwood J. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000; 11: 577–582
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Burris H A, III, Scullin D C, Jr, Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar